

Analyst meet update: Camlin Fine Sciences Ltd. (CFS)	Nov. 17, 2018

We recently attended the analyst meet of Camlin Fine Sciences Ltd. held on Nov. 16, 2018. The following are the highlights of the meet:

- 1) CMP: Rs. 56
- 2) FV: Re. 1
- 3) Book value: Rs. 36
- 4) Market Cap: Rs. 681 crores
- 5) FY18 topline: Rs. 723 crores
- 6) H1FY19 topline: Rs. 383 crores
- 7) Equity Capital: Rs. 12.12 crores
- 8) Networth: Rs. 369 crores
- 9) Net Fixed Assets: Rs. 201 crores
- 10)Total Debt: Rs. 426 crores as on H1FY19..(Short term borrowings: Rs. 228 crores), Inventory: Rs. 291 crores
- 11) Turned profit making in Q2FY19...

Key participants from company side along with respective department heads:

Mr. Ashish Dandekar - MD, over 28 years of experience in Pharma..(Was silent in analyst meeting)

Mr. Nirmal Momaya - Non Executive Director - Qualified CA with over 25 years of experience in the field of finance, taxation, audit and management consultancy and has been advising the company on strategic matters since 2009, Founder of Pagoda Advisors, a consulting firm providing consultancy services to Chemicals, Healthcare, Real Estate, Pharmaceuticals, QSR, FMCG sectors etc. - **Was answering all the questions and presented all the key developments**)

- 1) Mr. Santosh Parab, CFO, CA over 25 years of experience..
- 2) Dr. Massimo Cupello Castagna Managing Director CFS Europe S.p.A
- 3) Jennifer Igou General Manager CFS North America LLC
- 4) Gautum Sapute Head Operations (Vanillin) CFS Wanglong Flavours (Ningbo) Co. Ltd
- 5) Luciano Monteiro General Manager CFS Do Brasil (South America)
- 6) Arturo Paulin General Manager Sales CFS Mexico



- a) Manufacturing facilities in India, Italy, Brazil, Mexico and China
- b) Over 30 years experience providing innovative solutions with a competitive advantage in fine sciences

c) Unique producer of fully vertically integrated products - Global player in shelf-life solutions across food, feed, pet-food and Bio Diesel

- d) World's leading producer of food antioxidants: TBHQ & BHA
- e) Serving in more than 80 countries
- f) World's 3rd largest producer of Vanillin

g) CFS markets its products in Europe, Asia Pacific (including India), North Africa, Middle East, South, Central and North America.

- h) Company is in transformation since last 2 years..
- i) Demerged this business in 2006 from Camlin into Camlin Finesciences.
- j) 3 years back deconstructed the Company and structured it..
- k) Switched off from Antioxidant API supplier to Antioxidant blend..
- I) Acquired business in Italy to get new revenue stream..
- m) Co expects growth after restructuring of business model..
- n) Into this business for last 30 years as low cost Antioxidant supplier
- o) World's leading producer of Raw material of Antioxidants
- p) More than 1000 customers globally
- q) 3rd largest producer of Vanillin which is used in Ice-cream
- r) Today it is a Small MNC getting into other geographies
- s) Reliable supplier for large MNCs
- t) Competitors not very transparent as to what goes into the product
- u) Significant milestone 2011 Acquired facility in Italy
- v) Started introducing several downstream products from 2013 -Diphenol
- w) In 2015, TBHQ blend business -Forward integration, take its Raw material, blend it and sell it to final user



x) 2016 - Acquired 65 percent stake Of a Company based in Mexico which had a portfolio of animal feed, Antioxidants..

y) 2017 - Acquired 51 percent of Company in China having Vanillin product

z) Preferred partner for USA based Lockheed Martin for customised products and looking for new relationships..

ab) Forward integration - Antioxidant TBHQ blends ..

Business segments Shelf life solutions

Lipid oxidation significantly impacts the flavour, odour and colour of your food. There are many factors which contribute to such an occurrence including the presence of oxygen, improper fatty acid composition and a variety of unsuitable processing, packing & storing conditions.

The addition of an antioxidant stops the chain reaction of oxidation from happening and engages the attention of attacking oxygen molecules through a process called 'scavenging free radicals'. So an antioxidant added to your food, does actually makes it taste better for longer.

Camlin Fine Sciences (CFS) has global expertise in the antioxidant industry and has been a trusted name for over 25 years. Today, it is a leading integrated manufacturer of TBHQ and BHA.

The Company's proficiency in technical and market expertise further leverages CFS' Vertically Integrated Platform to give complete traceability and transparency in the manufacturing process from raw material to finished product.

The Company's blends of food antioxidants helps it to retain the goodness in food by extending its shelf life.

Performance chemicals - 34 percent of topline

With a capacity increase of Diphenols by almost 100% at its CFS plant, Italy has opened its doors to reach out to wide array of industries, enhancing its applications and also considerable improvement in energy efficiency. With the start of our CFS Italy plant in 2011, Performance Chemicals could meet its captive requirements of key raw materials Hydroquinone and Catechol. The vertical integration has enabled access and supplies to Europe, United States, Latin America, China, Japan, Middle East, Korea and South East Asia. The Performance Chemicals Division provides specialty chemicals like Guaiacol, Veratrole, TBC, MEHQ, ODEB, CME, 4-MAP, TBHQ Technical, Hydroquinone and Catechol. With this portfolio of specialty chemicals, the Performance Chemicals Division caters globally to industries including Petrochemicals, Pharmaceuticals, Flavours & Fragrances, Agrochemicals & Dyes.

Aroma ingredients -15 percent of topline

- 1) 3 rd largest vanillin manufacturers in the world with 100% backward integration
- 2) CFS has its manufacturing base in China and India.
- 3) Leveraging the existing global presence in shelf life solutions for expanding the aroma business
- 4) Vanillin, one of the most popular flavours is widely used in bakery, confectionery and nutritional products



5) Ethyl Vanillin, is 3 times more potent than vanillin and offers a more concentrated flavour profile

Upcoming capex:

Building 10,000 MT in Dahej for Hydroquinone and Cat..- learnings from Italy being implemented in Dahej.. investment Rs. 150 crores, Business potential from Dahej - Rs. 300 crores

Once Dahej comes up, and derivatives from Dahej can add upto Rs. 400-Rs. 500 crores topline

Value chain

- 1) Buying Phenol convert to Hydroquinone -TBHQ and their blends..
- 2) Buying Phenol and selling Vanillin..
- 3) Performance chemicals entered with Lockheed Martin
- 4) Competitors Large MNC Solvay
- 5) Volatility in business depends upon Benzene market (China new plants are coming which would make it balance)
- 6) For some clients, contractual agreements for yearly (pricing is not fixed, it is only the volume that is fixed, for pricing there is a formula)but not more than 2 years..

Growth strategy

- 1) Shift in focus from anti-oxidant ingredients to anti-oxidant blends and additives
- 2) Continue to grow the Vanillin business
- 3) Capacity expansion through new plant at Dahej SEZ
- 4) Increase revenue contribution from Performance Chemicals business
- 5) Integrate the strategic acquisitions for long term value growth
- 6) Improving market share and new product launches



Disclaimer

Ajcon Global Services Ltd. is a fully integrated investment banking, merchant banking, corporate advisory, stock broking, commodity and currency broking. Ajcon Global Services Ltd. research analysts responsible for the preparation of the research report may interact with trading desk personnel, sales personnel and other parties for gathering, applying and interpreting information.

Ajcon Global Services Ltd. is a SEBI registered Research Analyst entity bearing registration Number INH000001170 under SEBI (Research Analysts) Regulations, 2014.

Individuals employed as research analyst by Ajcon Global Services Ltd. or their associates are not allowed to deal or trade in securities that the research analyst recommends within thirty days before and five days after the publication of a research report as prescribed under SEBI Research Analyst Regulations.

Subject to the restrictions mentioned in above para, We and our affliates, officers, directors, employees and their relative may: (a) from time to time, have long or short positions acting as a principal in, and buy or sell the securities or derivatives thereof, of Company mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage.

Ajcon Global Services Ltd. or its associates may have commercial transactions with the Company mentioned in the research report with respect to advisory services.

The information and opinions in this report have been prepared by Ajcon Global Services Ltd. and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Ajcon Global Services Ltd. While we would endeavour to update the information herein on a reasonable basis, Ajcon Global Services Ltd. is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Ajcon Global Services Ltd. from doing so. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Ajcon Global Services Ltd. will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Ajcon Global Services Ltd. accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Ajcon Global Services Ltd. or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

Ajcon Global Services Ltd. encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Ajcon Global Services Ltd. or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Ajcon Global Services Ltd. nor Research Analysts have any material conflict of interest at the time of publication of this report.



It is confirmed that Akash Jain – MBA (Financial Markets) or any other Research Analysts of this report has not received any compensation from the company mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Ajcon Global Services Ltd. or its subsidiaries collectively or Directors including their relatives, Research Analysts, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

It is confirmed that Akash Jain – MBA (Financial Markets) research analyst or any other Research Analysts of Ajcon Global do not serve as an officer, director or employee of the companies mentioned in the report.

Ajcon Global Services Ltd. may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor Ajcon Global Services Ltd. have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on Ajcon Global Services Ltd. by any Regulatory Authority impacting Equity Research Analysis activities.

Analyst Certification

I, Akash Jain MBA (Financial Markets), research analyst, author and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. I also certify that no part of compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view (s) in this report.

For research related queries contact:

Mr. Akash Jain - Vice President (Research) at, 022-67160431 (D)

CIN: L74140MH1986PLC041941

SEBI registration Number: INH000001170 as per SEBI (Research Analysts) Regulations, 2014.

Website: www.ajcononline.com

Corporate and Broking Division

408 - (4th Floor), Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall and Patel's, Western Express Highway, Goregaon (East), Mumbai – 400063. Tel: 91-22-67160400, Fax: 022-28722062

Registered Office:

101, Samarth, Off. Hinduja Hospital, 151 Lt. P.N. Kotnis Road, Mahim (West), Mumbai – 400016. Tel: 022-24460335/36/40